Real-World Evidence, Market Access, Pricing & Reimbursement Global Congress 2021 Europe

Miriam Luz

Head of Market Access, Biogen

Nazanin Mehin

Global Head, Value & Access, Diabetes & Cardiovascular, Sanofi

Gina Ewy

Head Global Market Access, Hansa Biopharma AB

Lucy Hoppe

Clinical Effectiveness Manager (Evidence Synthesis), Group Clinical, BUPA

Nicki Catterick

Senior Director, Global Market Access and Pricing, Merck

Saira A. Jan

Director, Enterprise Pharmacy, Horizon Blue Cross Blue Shield of New Jersey

Sandro Cesaro-Tadic

Head Global Pricing I8 & Product Pricing Strategies, F. Hoffmann-La Roche

Scroll to Top

Dr. Marco Penske

Head. Market Access & Healthcare Affairs, Boehringer Ingelheim

Dr Marco Penske has been the Head of Market Access and Healthcare Affairs at Boehringer Ingelheim since 2011. Dr Penske studied Economics at Johannes Gutenberg University Mainz, focussing on Health

Economics and Statistics. Afterwards, he worked as a research assistant for the chair of Finance and Economics at the university. Following his promotion in the field of healthcare systems, he was employed at a business consultancy company. In 2007, he joined Boehringer Ingelheim and gained experience within several Market Access functions. In his current role, he is responsible for benefit

assessments and price negotiation in accordance with AMNOG, developing pricing strategies and contract models for pharmaceuticals, real world evidence and outcomes research as well as healthcare affairs activities and Key Account Management. In addition, he is an active speaker at congresses and works as a lecturer.

Ryotara Ishikawa-Oka

Global Market Access Director, Novartis Pharma AG

More than 15 years of experience in pharmaceutical industry in different geographies around the world, held several positions in commercial, marketing, sales and market access. Physician by training, post-graduate in Hospital Administration and Executive MBA from Universidad de Los Andes, EQUIS-Accredited. Lead several innovation projects for Novartis in Latin –America, Europe and Asia Pacific.

Dr. Alexander Natz

LL.M., Secretary General, European Confederation of Pharmaceutical Entrepreneurs (www.eucope.org)

Alexander Natz is the Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (www.eucope.org) in Brussels and works as a lawyer in the healthcare boutique law firm NOVACOS in Düsseldorf (www.novacos-law.com). He advises innovative pharmaceutical and biotech companies, including start-ups, in regulatory and pricing & reimbursement matters from the EU law and German law perspective.

From 2008 to 2013, he was Head of the Brussels Office of Bundesverband der Pharmazeutischen Industrie e.V. (BPI). Before, he has been a lawyer at Sträter Law Firm in Germany with a special focus on managed entry agreements and licensing of pharmaceuticals. Alexander has also worked in the field of competition law with the European Commission and in the pharmaceutical industry.

As a research assistant at Duke University (USA) he has dealt with international pharmaceutical law. His doctorate was supervised by the former judge at the European Court of Justice, Prof. Dr. Dr. Ulrich Everling.

Alexander represents innovative life sciences companies at the EU institutions, before national authorities, HTA agencies, payers and courts. Alexander has a particular expertise in EU regulatory law such as GMP, lifecycle management, distribution and clinical trials, as well as in pricing and reimbursement procedures in Germany. He advises several US biotech and medtech companies in market access & government affairs related issues in Germany, offering strategic advice on value demonstration, pricing, tendering and other reimbursement matters. Alexander offers full-service legal support throughout all phases of the AMNOG-procedure, including drafting of dossier, G-BA benefit assessment, price negotiations with the GKV-Spitzenverband and arbitration board proceedings. He has a particular expertise in orphan drugs, medical devices as well as gene & cell therapies. His work also focuses on strategies for early value demonstration towards payers and national HTA bodies next to early patient engagement.

Giovanny Leon

Pricing and Access Director, Latin America & Canada, Novartis AG

Giovanny is a pharmaceutical executive with intensive experience in a variety of management roles in LatAm and the Novartis Global HQ. He is passionate about improving patient access to medicines in emerging markets, with strong focus on affordability challenges for low and middle-income economies.

He strongly believe in “walk-the-talk” and learning by doing in digital leadership change, that’s why he’s very active in Twitter, LinkedIn and other social media platforms.

He has an MBA and a Master in Marketing and Commercial Management from Universidad Complutense, Madrid and has completed several Management & Leadership programs from University of Cambridge, London Business School, Columbia University, IESA, Universidad de Los Andes, ITAM, ESPM, IAE.

Amer Omar

Senior Director, Head of EMEA Value Access, Pricing and Public Affairs, NeuroScience, Lupin

Amer is the head of EMA region for access and pricing for Lupin Pharmaceuticals. He is leading on genetics and rare disease products launch. With extensive experience in specialty, he has been working at the forefront of bringing new and innovative solutions in market access, pricing and evidence generation to allow patients gaining access to life saving solutions.

Anne Marciniak

Senior Director, Head of EU Market Access, Aimmune Therapeutics Ltd

Anne is currently Senior Director, Head of EU market Access with Aimmune Therapeutics Ltd. She has over 20-year experience in Market Access and Health Economics in the pharmaceutical industry, including Pfizer, Amgen, Daiichi-Sankyo and recently Allergan. With her teams, she lead the Market Access strategy of an innovative Peanut Allergy immunotherapy across Europe She focused on meeting the needs of and engaging payers at national, regional and local levels. She has hands-on experience in establishing strategies and leading their cross-functional execution, integrating all elements of product value in particular clinical and safety profile, health economics and price. She believes that through engagement of all partners involved in the delivery of health care including payers the best value will be achieved for patients and citizens ultimately financing care. She is a physician by training with qualification in Health Economics and Epidemiology.

Dan Jackson

Principal Statistical Methodology Expert, AstraZeneca

Dan Jackson is a Principal Statistical Methodology Expert at AstraZeneca. Prior to joining AstraZeneca, he was a Senior Statistician at the MRC Biostatistics Unit Cambridge. His primary research interest is statistical methodology for performing meta-analyses. In total he has published over 90 papers in peer reviewed journals and his google scholar profile records his h-index to be 33. Dan has considerable teaching experience, having been previously employed as a University lecturer and as a secondary school mathematics teacher.

Marie Kane

Director of Corporate Strategy & Deputy CEO, NorthWest EHealth

Marie has over 20 years’ experience of delivering process improvement and organisational change working in the public sector including 10 years in the NHS. Marie has been with NWEH for five years, with most of that time as Chief Operating Officer, leading the transformation of the business from an academic project to a commercial corporation.

Marie now leads on corporate strategy and business development. Marie is a Director of the company.